Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer.

Bierie B, Moses HL.

Nat Rev Cancer. 2006 Jul;6(7):506-20. Review.

PMID:
16794634
2.

TGFbeta and cancer metastasis: an inflammation link.

Yang L.

Cancer Metastasis Rev. 2010 Jun;29(2):263-71. doi: 10.1007/s10555-010-9226-3. Review.

PMID:
20437081
3.

Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis.

Gal A, Sjöblom T, Fedorova L, Imreh S, Beug H, Moustakas A.

Oncogene. 2008 Feb 21;27(9):1218-30. Epub 2007 Aug 27.

PMID:
17724470
4.

The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGFbeta.

Dumont N, Arteaga CL.

Differentiation. 2002 Dec;70(9-10):574-82. Review.

PMID:
12492498
5.

Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment.

Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K, Shirai T.

Cancer Sci. 2008 Feb;99(2):316-23. doi: 10.1111/j.1349-7006.2007.00690.x.

6.

Targeting TGFbeta-mediated processes in cancer.

Romano MF.

Curr Opin Drug Discov Devel. 2009 Mar;12(2):253-63. Review.

PMID:
19333871
7.

The TGFBeta pathway as a therapeutic target in cancer.

Seoane J.

Clin Transl Oncol. 2008 Jan;10(1):14-9. Review.

PMID:
18208788
8.
9.

Roles of TGFbeta in metastasis.

Padua D, Massagué J.

Cell Res. 2009 Jan;19(1):89-102. doi: 10.1038/cr.2008.316. Review.

PMID:
19050696
10.

A delicate balance: TGF-beta and the tumor microenvironment.

Stover DG, Bierie B, Moses HL.

J Cell Biochem. 2007 Jul 1;101(4):851-61. Review.

PMID:
17486574
11.

Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures.

Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NA, Picariello L, Cazzola P, Monteleone G, Tonelli F, Corazza GR, MacDonald TT, Pender SL.

Gut. 2009 Jun;58(6):777-89. doi: 10.1136/gut.2008.149096. Epub 2009 Feb 6.

PMID:
19201776
12.

Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.

Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, O'Young G, Quon D, Henson M, Damm DL, Muiru GT, Murphy A, Higgins LS, Chakravarty S, Wong DH.

Mol Pharmacol. 2007 Jul;72(1):152-61. Epub 2007 Mar 30.

13.

Inhibition of TGFbeta signaling in cancer therapy.

Arteaga CL.

Curr Opin Genet Dev. 2006 Feb;16(1):30-7. Epub 2005 Dec 27. Review.

PMID:
16377175
14.

Escaping from the TGFbeta anti-proliferative control.

Seoane J.

Carcinogenesis. 2006 Nov;27(11):2148-56. Epub 2006 May 12. Review.

PMID:
16698802
15.

The not-so innocent bystander: the microenvironment as a therapeutic target in cancer.

Erickson AC, Barcellos-Hoff MH.

Expert Opin Ther Targets. 2003 Feb;7(1):71-88. Review.

PMID:
12556204
16.

TGFbeta signalling: a complex web in cancer progression.

Ikushima H, Miyazono K.

Nat Rev Cancer. 2010 Jun;10(6):415-24. doi: 10.1038/nrc2853. Review.

PMID:
20495575
17.

TGF beta inhibition for cancer therapy.

Saunier EF, Akhurst RJ.

Curr Cancer Drug Targets. 2006 Nov;6(7):565-78. Review.

PMID:
17100564
18.

Jekyll and Hyde: the role of the microenvironment on the progression of cancer.

Allen M, Louise Jones J.

J Pathol. 2011 Jan;223(2):162-76. doi: 10.1002/path.2803. Epub 2010 Oct 29. Review.

PMID:
21125673
19.

The role of epithelial-mesenchymal transition in cancer pathology.

Guarino M, Rubino B, Ballabio G.

Pathology. 2007 Jun;39(3):305-18. Review.

PMID:
17558857
20.

TGFbeta signalling in control of T-cell-mediated self-reactivity.

Rubtsov YP, Rudensky AY.

Nat Rev Immunol. 2007 Jun;7(6):443-53. Review.

PMID:
17525753

Supplemental Content

Support Center